7/106 sources · 6 publishersUpdated Nov 3, 10:35 UTC
Teva halts Phase 2 emrusolmin trial for multiple system atrophy after futility analysis
Teva announced it will discontinue its Phase 2 TOPAS-MSA study of emrusolmin (TEV‑286) in adults with multiple system atrophy. The stop follows a prespecified interim futility analysis that met the predefined criterion, as recommended by an independent data monitoring committee. No safety concerns were identified. The decision does not affect the broader emrusolmin program.
Why it matters
The halt removes a potential future product from Teva’s pipeline, reducing near‑term revenue prospects from a rare‑disease therapy. Investors saw the share price dip about 3% in pre‑market trading after the announcement.
Key facts
- 1Teva will discontinue the Phase 2 TOPAS-MSA study (NCT06568237) of emrusolmin (TEV‑286) in adults with multiple system atrophy. globenewswire.com
- 2The decision follows a recommendation from an independent data monitoring committee after a prespecified interim futility analysis that met the predefined futility criterion. globenewswire.com
- 3No safety concerns were identified in the interim analysis. globenewswire.com
- 4The study was designed to enroll approximately 350 participants to receive 300 mg emrusolmin or placebo for about 48 weeks. investing.com
- 5Teva’s shares fell about 3% in pre‑market trading after the announcement. investing.com
- 6Emrusolmin is being developed in partnership with MODAG GmbH and has U.S. FDA orphan drug designation (2022) and Fast Track designation (Sept 2025). globenewswire.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.